


L5 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:138640 CAPLUS Full-text
 DN 146:229389
 TI Preparation of benzodiazepine derivatives having PDE2 inhibitory activities
 IN Abarghaz, Mustapha; Biondi, Stefano; Durantou, Jerome; Mondadori, Cesare; Wagner, Patrick
 PA Neuro3d, Fr.
 SO Eur. Pat. Appl., 36pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1749824	A1	20070207	EP 2005-291658	20050803
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	WO 2007026254	A2	20070308	WO 2006-IB3295	20060802
	WO 2007026254	A3	20070705		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI	EP 2005-291658	A	20050803		
OS	MARPAT 146:229389				
GI					



AB The title compds. I [R1 = H, alkyl, aryl, etc.; R2 = H, halo, alkyl, etc.; R3 = H, alkyl, haloalkyl; R4 = (un)substituted (hetero)aryl] having PDE2 inhibitory activities and therefore useful in particular for treating various diseases of the central or peripheral nervous system, were prepared E.g., a multi-step synthesis of I [R1 = Me; R2 = 3-CONH2; R3 = Me; R4 = 4-ClC6H4], starting from 4-bromo-3,5-dimethoxyphenylamine and 4-chlorophenylboronic acid, was given. The mentioned above exemplified compound I showed 98% PDE2 inhibition at 10 μ M. Pharmaceutical compns. comprising said compds. I are disclosed.

IT 923957-84-0P 923957-85-1P 923957-86-2P
 923957-87-3P 923957-88-4P 923957-89-5P
 923957-90-8P 923957-91-9P 923957-93-1P
 923957-94-2P 923957-95-3P 923957-97-5P
 923957-98-6P 923957-99-7P 923958-00-3P


923958-11-6P 923958-12-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted benzodiazepinones with PDE2 inhibitory activity and useful in treating various diseases of central or peripheral nervous system)


RN 923957-84-0 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 923957-85-1 CAPLUS

CN Benzonitrile, 3-[7-(4-chlorophenyl)-2,3-dihydro-6,8-dimethoxy-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923957-86-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-6,8-dimethoxy-5,7-diphenyl- (CA INDEX NAME)




RN 923957-87-3 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-(3-pyridinyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923957-88-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3-bromophenyl)-1,3-dihydro-6,8-dimethoxy-7-phenyl- (CA INDEX NAME)




RN 923957-89-5 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 923957-90-8 CAPLUS

CN Benzonitrile, 3-[7-(4-chlorophenyl)-2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923957-91-9 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-7-(3-pyridinyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923957-93-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3-bromophenyl)-1,3-dihydro-6,8-dimethoxy-1-methyl-7-phenyl- (CA INDEX NAME)




RN 923957-94-2 CAPLUS

CN Benzonitrile, 3-(1-ethyl-2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 923957-95-3 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-propyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 923957-97-5 CAPLUS

CN Benzonitrile, 3-[1-(cyclopropylmethyl)-2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923957-98-6 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-(phenylmethyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923957-99-7 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-[[4-(trifluoromethyl)phenyl]methyl]-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-00-3 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-(3-phenylpropyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-11-6 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-6,8-dimethoxy-5-[3-(3-methoxy-1-propyn-1-yl)phenyl]-1-methyl-7-phenyl- (CA INDEX NAME)



RN 923958-12-7 CAPLUS

CN Carbamic acid, N-[3-[3-(2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)phenyl]-2-propyn-1-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 923957-92-0P 923958-01-4P 923958-02-5P

923958-03-6P 923958-04-7P 923958-05-8P

923958-06-9P 923958-07-0P 923958-08-1P

923958-09-2P 923958-10-5P 923958-13-8P


923958-15-0P 923958-17-2P 923958-18-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of substituted benzodiazepinones with PDE2 inhibitory activity and useful in treating various diseases of central or peripheral nervous system)


RN 923957-92-0 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-6,8-dimethoxy-1-methyl-5,7-diphenyl- (CA INDEX NAME)




RN 923958-01-4 CAPLUS

CN Benzamide, 3-(2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 923958-02-5 CAPLUS

CN Benzamide, 3-[7-(4-chlorophenyl)-2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-03-6 CAPLUS

CN Benzamide, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-(3-pyridinyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-04-7 CAPLUS

CN Benzamide, 3-[2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-7-(3-pyridinyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-05-8 CAPLUS

CN Benzamide, 3-(1-ethyl-2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 923958-06-9 CAPLUS

CN Benzamide, 3-(2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-propyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 923958-07-0 CAPLUS

CN Benzamide, 3-[1-(cyclopropylmethyl)-2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-08-1 CAPLUS

CN Benzamide, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-(phenylmethyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-09-2 CAPLUS

CN Benzamide, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-[[4-(trifluoromethyl)phenyl]methyl]-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 923958-10-5 CAPLUS

CN Benzamide, 3-[2,3-dihydro-6,8-dimethoxy-2-oxo-7-phenyl-1-(3-phenylpropyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)



RN 923958-13-8 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-6,8-dimethoxy-5-[3-(3-methoxypropyl)phenyl]-1-methyl-7-phenyl- (CA INDEX NAME)



RN 923958-15-0 CAPLUS


CN Carbamic acid, N-[3-[3-(2,3-dihydro-6,8-dimethoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)phenyl]propyl]-, 1,1-dimethylethyl ester (CA

INDEX NAME)




RN 923958-17-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-[3-(3-amino-1-propyn-1-yl)phenyl]-1,3-dihydro-6,8-dimethoxy-1-methyl-7-phenyl- (CA INDEX NAME)



RN 923958-18-3 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 5-[3-(3-aminopropyl)phenyl]-1,3-dihydro-6,8-dimethoxy-1-methyl-7-phenyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:568974 CAPLUS Full-text
 DN 143:78216
 TI Preparation of benzo[1,4]diazepin-2-one derivatives as phosphodiesterase
 PDE2 inhibitors
 IN Abarghaz, Mustafa; Biondi, Stefano; Durantou, Jerome; Limanton,
 Emmanuelle; Mondadori, Cesare; Wagner, Patrick
 PA Neuro3d, Fr.
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1548011	A1	20050629	EP 2003-293309	20031223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AU 2004309173	A1	20050714	AU 2004-309173	20041223
	CA 2548318	A1	20050714	CA 2004-2548318	20041223
	WO 2005063723	A1	20050714	WO 2004-IB4362	20041223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1697332	A1	20060906	EP 2004-806522	20041223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	CN 1898217	A	20070117	CN 2004-80038085	20041223
	BR 2004018099	A	20070417	BR 2004-18099	20041223
	JP 2007516276	T	20070621	JP 2006-546406	20041223
	IN 2006DN02955	A	20070810	IN 2006-DN2955	20060523
	US 2007123519	A1	20070531	US 2006-582131	20060608
PRAI	EP 2003-293309	A	20031223		
	WO 2004-IB4362	W	20041223		
OS	MARPAT 143:78216				
GI					



I

AB Title compds. I [R1 = H, alkyl, aryl, etc.; R7 = (hetero)aryl; R8 = H, alkoxy, etc.; R5 = H, halo, alkyl, etc.; R6 = H, halo, Me, etc.] are prepared For instance, 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzonitrile (II) is prepared from 3-(7-bromo-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzonitrile

(preparation given) and benzenboronic acid. II has IC50 = 0.57 for PDE2. Selected compds. exhibit selectivity for binding to PDE2 vs. PDE3 and PDE4. I are useful for treating various diseases of the central or peripheral nervous system.


IT 855168-38-6P, 5-(4-Methoxyphenyl)-8-methoxy-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855168-64-8P, 5-(3-Bromophenyl)-8-methoxy-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855168-67-1P, 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzonitrile 855168-70-6P, 3-[7-(4-Fluorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855168-73-9P, 3-[8-Methoxy-7-(2-methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855168-77-3P, 3-[8-Methoxy-7-(4-methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855168-81-9P, 3-[7-(2-Chlorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855168-88-6P, 3-[7-(3-Chlorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855168-92-2P, 3-[7-(4-Chlorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855168-96-6P, 3-(7-(Furan-2-yl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzonitrile 855169-08-3P, 3-[8-Methoxy-7-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-12-9P, 3-(1-Methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzonitrile 855169-16-3P, 3-[7-(2-Methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-20-9P, 3-[7-(3-Methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-24-3P, 3-[7-(4-Methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-27-6P, 3-[7-(2,5-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-31-2P, 3-[7-(2,6-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-35-6P, 3-[7-(2,4-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-56-1P, 3-[8-Methoxy-1-methyl-2-oxo-7-(4-cyanophenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-59-4P, 3-[7-(4-Acetylphenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855169-78-7P, 3-[7-(3,4-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855170-10-4P, 3-[7-(2-Isopropoxyphenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855170-18-2P, 1-Methyl-5-(3-nitrophenyl)-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-25-1P, 3-(1-Methyl-2-oxo-8-phenoxy-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzonitrile 855170-30-8P, 3-[7-(2-Methoxyphenyl)-1-methyl-2-oxo-8-phenoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855170-32-0P, 3-[7-(2-Chlorophenyl)-1-methyl-2-oxo-8-phenoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855170-47-7P, 3-[7-(5-Chloro-2-methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855170-50-2P, 3-[7-(2-Chloro-6-methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855171-17-4P, 3-[1-Benzyl-8-methoxy-7-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855171-25-4P, 3-[8-Methoxy-7-(2-methoxyphenyl)-2-oxo-1-propyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855171-32-3P,

3-[8-Methoxy-7-(2-methoxyphenyl)-2-oxo-1-phenethyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile 855171-40-3P,
3-[1-Hexyl-8-methoxy-7-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzonitrile

RL: PAC (Pharmacological activity); RCT (Réactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzo[1,4]diazepin-2-one derivs. as (selective) phosphodiesterase PDE2 inhibitors)


RN 855168-38-6 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-8-methoxy-5-(4-methoxyphenyl)-7-phenyl- (CA INDEX NAME)




RN 855168-64-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3-bromophenyl)-1,3-dihydro-8-methoxy-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855168-67-1 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-8-methoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 855168-70-6 CAPLUS

CN Benzonitrile, 3-[7-(4-fluorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855168-73-9 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855168-77-3 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-8-methoxy-7-(4-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855168-81-9 CAPLUS

CN Benzonitrile, 3-[7-(2-chlorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855168-88-6 CAPLUS

CN Benzonitrile, 3-[7-(3-chlorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855168-92-2 CAPLUS

CN Benzonitrile, 3-[7-(4-chlorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855168-96-6 CAPLUS

CN Benzonitrile, 3-[7-(2-furanyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-08-3 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-12-9 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 855169-16-3 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-7-(2-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-20-9 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-7-(3-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-24-3 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-7-(4-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-27-6 CAPLUS

CN Benzonitrile, 3-[7-(2,5-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-31-2 CAPLUS

CN Benzonitrile, 3-[7-(2,6-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-35-6 CAPLUS

CN Benzonitrile, 3-[7-(2,4-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-56-1 CAPLUS

CN Benzonitrile, 3-[7-(4-cyanophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-59-4 CAPLUS

CN Benzonitrile, 3-[7-(4-acetylphenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-78-7 CAPLUS

CN Benzonitrile, 3-[7-(3,4-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-10-4 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-8-methoxy-1-methyl-7-[2-(1-methylethoxy)phenyl]-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-18-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-5-(3-nitrophenyl)-7-phenyl- (CA INDEX NAME)




RN 855170-25-1 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-1-methyl-2-oxo-8-phenoxy-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 855170-30-8 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-7-(2-methoxyphenyl)-1-methyl-2-oxo-8-phenoxy-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-32-0 CAPLUS

CN Benzonitrile, 3-[7-(2-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-8-phenoxy-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-47-7 CAPLUS

CN Benzonitrile, 3-[7-(5-chloro-2-methoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-50-2 CAPLUS

CN Benzonitrile, 3-[7-(2-chloro-6-methoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-17-4 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1-(phenylmethyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-25-4 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-32-3 CAPLUS

CN Benzonitrile, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1-(2-phenylethyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)



RN 855171-40-3 CAPLUS

CN Benzonitrile, 3-[1-hexyl-2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)



IT 855169-00-5P, 3-(1-Methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzaldehyde 855169-39-0P, 8-Ethoxy-1-ethyl-5,7-diphenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-43-6P, 5-(3-Chlorophenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-48-1P, 5-(2-Chlorophenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-52-7P, 5-(4-Chlorophenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-63-0P, 5-(4-Methoxyphenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-67-4P, 5-(2-Methoxyphenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-70-9P, 3-[7-(Furan-2-yl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-


yl]benzonitrile 855169-82-3P, 5-(3,5-Dichlorophenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-86-7P, 5-(3,4-Dichlorophenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-90-3P, 5-(4-Fluorophenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-94-7P, 5-(3-Acetylphenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855169-98-1P, 1-Methyl-7-phenyl-5-(3-trifluoromethylphenyl)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-02-4P, 1-Methyl-5-(4-methyl-3-nitrophenyl)-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-07-9P, 1-Methyl-7-phenyl-5-(4-trifluoromethoxyphenyl)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-14-8P, 5-(3,4-Dimethoxyphenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-22-8P, 5-(3-Aminophenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-36-4P, 7-(2,6-Dimethoxyphenyl)-5-(4-methoxyphenyl)-1-methyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-41-1P, 7-(2,6-Dimethoxyphenyl)-1-methyl-5-(4-methyl-3-nitrophenyl)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-44-4P, 5-(3-Methoxyphenyl)-1-methyl-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 855170-53-5P, 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzamide 855170-56-8P, 3-(7-(4-Fluorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzamide 855170-59-1P, 3-[8-Methoxy-7-(2-methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-62-6P, 3-[8-Methoxy-7-(4-methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-65-9P, 3-[7-(2-Chlorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-68-2P, 3-[7-(3-Chlorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-72-8P, 3-[7-(4-Chlorophenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-74-0P, 3-(7-(Furan-2-yl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzamide 855170-77-3P, 3-(1-Methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)benzamide 855170-80-8P, 3-[7-(2-Methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-84-2P, 3-[7-(3-Methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-88-6P, 3-[7-(4-Methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-93-3P, 3-[7-(2,5-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855170-96-6P, 3-[7-(2,6-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-00-5P, 3-[7-(2,4-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-05-0P, 3-[8-Methoxy-7-(4-benzamido)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-09-4P, 3-[8-Methoxy-7-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-13-0P, 3-[1-Benzyl-8-methoxy-7-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-21-0P, 3-[8-Methoxy-7-(2-methoxyphenyl)-2-oxo-1-propyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-29-8P, 3-[8-Methoxy-7-(2-methoxyphenyl)-2-oxo-1-phenethyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-36-7P, 3-[1-Hexyl-8-methoxy-7-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-44-7P, 3-[7-(4-Acetylphenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-

benzo[e][1,4]diazepin-5-yl]benzamide 855171-48-1P,
 3-[7-(3,4-Dimethoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-5-yl]benzamide 855171-52-7P,
 3-(1-Methyl-2-oxo-8-phenoxy-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-
 5-yl)benzamide 855171-56-1P, 3-[7-(2-Chlorophenyl)-1-methyl-2-
 oxo-8-phenoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide
 855171-60-7P, 3-[7-(2-Methoxyphenyl)-1-methyl-2-oxo-8-phenoxy-2,3-
 dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-64-1P
 855171-68-5P, 3-[7-(5-Chloro-2-methoxyphenyl)-1-methyl-2-oxo-2,3-
 dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide 855171-72-1P,
 3-[7-(2-Chloro-6-methoxyphenyl)-1-methyl-2-oxo-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-5-yl]benzamide 855171-76-5P,
 5-(3-Hexan-1-ynylphenyl)-8-methoxy-1-methyl-7-phenyl-1,3-
 dihydrobenzo[e][1,4]diazepin-2-one 855171-79-8P,
 [3-[3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-
 benzo[e][1,4]diazepin-5-yl)phenyl]prop-2-ynyl]carbamic acid tert-butyl
 ester 855171-83-4P, 3-[8-Methoxy-7-(4-benzamido)-1-methyl-2-oxo-
 2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of benzo[1,4]diazepin-2-one derivs. as (selective)
 phosphodiesterase PDE2 inhibitors)


RN 855169-00-5 CAPLUS

CN Benzaldehyde, 3-(2,3-dihydro-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-
 5-yl)- (CA INDEX NAME)




RN 855169-39-0 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 8-ethoxy-1-ethyl-1,3-dihydro-5,7-diphenyl-
 (CA INDEX NAME)




RN 855169-43-6 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 5-(3-chlorophenyl)-1,3-dihydro-1-methyl-7-
 phenyl- (CA INDEX NAME)




RN 855169-48-1 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)



RN 855169-52-7 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 5-(4-chlorophenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855169-63-0 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-(4-methoxyphenyl)-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855169-67-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-(2-methoxyphenyl)-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855169-70-9 CAPLUS

CN Benzonitrile, 3-[7-(2-furanyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855169-82-3 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3,5-dichlorophenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855169-86-7 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3,4-dichlorophenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855169-90-3 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(4-fluorophenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855169-94-7 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3-acetylphenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855169-98-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-7-phenyl-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 855170-02-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-5-(4-methyl-3-nitrophenyl)-7-phenyl- (CA INDEX NAME)




RN 855170-07-9 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-7-phenyl-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 855170-14-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3,4-dimethoxyphenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855170-22-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3-aminophenyl)-1,3-dihydro-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855170-36-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 7-(2,6-dimethoxyphenyl)-1,3-dihydro-5-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)




RN 855170-41-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 7-(2,6-dimethoxyphenyl)-1,3-dihydro-1-methyl-5-(4-methyl-3-nitrophenyl)- (CA INDEX NAME)




RN 855170-44-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-(3-methoxyphenyl)-1-methyl-7-phenyl- (CA INDEX NAME)




RN 855170-53-5 CAPLUS

CN Benzamide, 3-(2,3-dihydro-8-methoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 855170-56-8 CAPLUS

CN Benzamide, 3-[7-(4-fluorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-59-1 CAPLUS

CN Benzamide, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-62-6 CAPLUS

CN Benzamide, 3-[2,3-dihydro-8-methoxy-7-(4-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-65-9 CAPLUS

CN Benzamide, 3-[7-(2-chlorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-68-2 CAPLUS

CN Benzamide, 3-[7-(3-chlorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-72-8 CAPLUS

CN Benzamide, 3-[7-(4-chlorophenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-74-0 CAPLUS

CN Benzamide, 3-[7-(2-furanyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-77-3 CAPLUS

CN Benzamide, 3-(2,3-dihydro-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 855170-80-8 CAPLUS

CN Benzamide, 3-[2,3-dihydro-7-(2-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-84-2 CAPLUS

CN Benzamide, 3-[2,3-dihydro-7-(3-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-88-6 CAPLUS

CN Benzamide, 3-[2,3-dihydro-7-(4-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-93-3 CAPLUS

CN Benzamide, 3-[7-(2,5-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855170-96-6 CAPLUS

CN Benzamide, 3-[7-(2,6-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-00-5 CAPLUS

CN Benzamide, 3-[7-(2,4-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-05-0 CAPLUS

CN Benzamide, 3-[7-[4-(aminocarbonyl)phenyl]-2,3-dihydro-8-methoxy-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-09-4 CAPLUS

CN Benzamide, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-13-0 CAPLUS

CN Benzamide, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1-(phenylmethyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-21-0 CAPLUS

CN Benzamide, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-29-8 CAPLUS

CN Benzamide, 3-[2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1-(2-phenylethyl)-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-36-7 CAPLUS

CN Benzamide, 3-[1-hexyl-2,3-dihydro-8-methoxy-7-(2-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-44-7 CAPLUS

CN Benzamide, 3-[7-(4-acetylphenyl)-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-48-1 CAPLUS

CN Benzamide, 3-[7-(3,4-dimethoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-52-7 CAPLUS

CN Benzamide, 3-(2,3-dihydro-1-methyl-2-oxo-8-phenoxy-7-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 855171-56-1 CAPLUS

CN Benzamide, 3-[7-(2-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-8-phenoxy-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-60-7 CAPLUS

CN Benzamide, 3-[2,3-dihydro-7-(2-methoxyphenyl)-1-methyl-2-oxo-8-phenoxy-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-64-1 CAPLUS

CN Benzamide, 3-[2,3-dihydro-8-methoxy-1-methyl-7-[2-(1-methylethoxy)phenyl]-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-68-5 CAPLUS

CN Benzamide, 3-[7-(5-chloro-2-methoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-72-1 CAPLUS

CN Benzamide, 3-[7-(2-chloro-6-methoxyphenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




RN 855171-76-5 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-[3-(1-hexynyl)phenyl]-1,3-dihydro-8-methoxy-1-methyl-7-phenyl- (9CI) (CA INDEX NAME)




RN 855171-79-8 CAPLUS

CN Carbamic acid, [3-[3-(2,3-dihydro-8-methoxy-1-methyl-2-oxo-7-phenyl-1H-1,4-benzodiazepin-5-yl)phenyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 855171-83-4 CAPLUS

CN Benzamide, 3-[7-[4-(aminocarbonyl)phenyl]-2,3-dihydro-8-methoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (CA INDEX NAME)




IT 855168-44-4P, 5-(3-Bromophenyl)-8-methoxy-7-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzo[1,4]diazepin-2-one derivs. as (selective) phosphodiesterase PDE2 inhibitors)

RN 855168-44-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 5-(3-bromophenyl)-1,3-dihydro-8-methoxy-7-phenyl- (CA INDEX NAME)




RE.CNT 2


THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:414716 CAPLUS Full-text
 DN 140:423714
 TI Preparation of benzodiazepinones as cyclic nucleotide phosphodiesterase,
 in particular PDE2 inhibitors, for treating central and peripheral nervous
 system diseases
 IN Bourguignon, Jean-Jacques; Lugnier, Claire; Abarghaz, Mustapha; Lagouge,
 Yan; Wagner, Patrick; Mondadori, Cesare; Macher, Jean-Paul; Schultz,
 Dominique; Raboisson, Pierre
 PA Neuro3d, Fr.; Universite Louis Pasteur; Centre National De La Recherche
 Scientifique; Forenap; et al.
 SO PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004041258	A2	20040521	WO 2003-FR3247	20031030
	WO 2004041258	A3	20040923		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				
	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				
	OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2846653	A1	20040507	FR 2002-13607	20021030
	FR 2846653	B1	20070420		
	CA 2503716	A1	20040521	CA 2003-2503716	20031030
	AU 2003288352	A1	20040607	AU 2003-288352	20031030
	EP 1556055	A2	20050727	EP 2003-780257	20031030
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006509832	T	20060323	JP 2005-502123	20031030
	NZ 540167	A	20070629	NZ 2003-540167	20031030
	US 2006128695	A1	20060615	US 2005-533157	20051207
PRAI	FR 2002-13607	A	20021030		
	US 2003-455874P	P	20030320		
	WO 2003-FR3247	W	20031030		
OS	MARPAT 140:423714				
GI					



I



II

AB Title compds. I [wherein Z = O, S, NR₂; R₁ = H, aryl/alkyl, alkyl/aryl; R₂ = H, aryl/alkyl, alkyl/aryl; R₃, R_{3'} = independently H, aryl/cyclo/alkyl, alkyl/aryl; heterocyclyl, NO₂, CF₃, CN, NH₂ and derivs., SH and derivs., OH and derivs.; CO₂H and derivs., CONH₂ and derivs., etc.; R₅ = naphthyl, heterocyclyl selected from pyridinyl, isoquinolinyl, quinolinyl, piperazinyl, (un)substituted Ph with provisos; R₇, R₈ = independently H, halo, OH and derivs. with at least one of R₇ and R₈ = OH and derivs.; R₆, R₉ = independently H, halo, OH and derivs., (un)substituted ar/heterocyclo/cyclo/alkyl, alkenyl, alkynyl, aryl, heterocyclyl; and their salts with certain compds. excluded] were prepared as cyclic nucleotide phosphodiesterase PDE2 inhibitors for treating central and peripheral nervous system disorders. Thus, benzodiazepinone II was prepared, in 90% yield, by cyclization of 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl)thiobenzamide (preparation given) with bromoacetophenone in EtOH. I inhibited the in vitro activity of bovine smooth muscle PDE2 by 91.4% at 10 μ M.


IT 685102-90-3P 685103-00-8P 685103-65-5P
685103-67-7P 685103-68-8P 685103-69-9P
685103-70-2P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE2 inhibitor; preparation of benzodiazepinones as cyclic nucleotide phosphodiesterase PDE2 inhibitors for treating nervous system disorders)

RN 685102-90-3 CAPLUS


CN Benzamide, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-6-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)



RN 685103-00-8 CAPLUS


CN Benzamide, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-9-phenyl-1H-1,4-

benzodiazepin-5-yl)- (CA INDEX NAME)



RN 685103-65-5 CAPLUS


CN Benzonitrile, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-9-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)



RN 685103-67-7 CAPLUS


CN 2-Propenoic acid, 3-[3-[5-(3-cyanophenyl)-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-9-yl]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 685103-68-8 CAPLUS

CN Carbamic acid, [3-[3-[5-(3-cyanophenyl)-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-6-yl]phenyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 685103-69-9 CAPLUS

CN Benzonitrile, 3-[9-[3-(3-amino-1-propynyl)phenyl]-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (9CI) (CA INDEX NAME)



RN 685103-70-2 CAPLUS

CN Benzonitrile, 3-[6-[3-(3-amino-1-propynyl)phenyl]-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (9CI) (CA INDEX NAME)




IT 685103-64-4P 685103-66-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nervous system agent; preparation of benzodiazepinones as cyclic nucleotide phosphodiesterase PDE2 inhibitors for treating nervous system disorders)


RN 685103-64-4 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-6-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)



RN 685103-66-6 CAPLUS

CN Carbamic acid, [3-[3-[5-(3-cyanophenyl)-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-9-yl]phenyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:370793 CAPLUS Full-text

DN 140:370818

TI Benzodiazepinone inhibitors of cyclic nucleotide phosphodiesterase PDE2
for use in treatment of nervous system disorders

IN Bourguignon, Jean Jacques; Lugnier, Claire; Abarghaz, Mustapha; Lagouge,
Yan; Wagner, Patrick; Mondadori, Cesare; Macher, Jean Paul; Schultz,
Dominique; Raboisson, Pierre

PA Neuro3d, Fr.

SO Fr. Demande, 126 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2846653	A1	20040507	FR 2002-13607	20021030
	FR 2846653	B1	20070420		
	CA 2503716	A1	20040521	CA 2003-2503716	20031030
	WO 2004041258	A2	20040521	WO 2003-FR3247	20031030
	WO 2004041258	A3	20040923		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003288352	A1	20040607	AU 2003-288352	20031030
	EP 1556055	A2	20050727	EP 2003-780257	20031030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006509832	T	20060323	JP 2005-502123	20031030
	NZ 540167	A	20070629	NZ 2003-540167	20031030
	ZA 2005005412	A	20060426	ZA 2005-5412	20050527
	US 2006128695	A1	20060615	US 2005-533157	20051207
PRAI	FR 2002-13607	A	20021030		
	US 2003-455874P	P	20030320		
	WO 2003-FR3247	W	20031030		

OS MARPAT 140:370818

AB The invention relates to benzodiazepinone inhibitors of PDE2 and their use in
treatment of disorders of the central and peripheral nervous system. Thus,
7,8-dimethyl-1-Me 5-[3-(4-phenyl-1,3-thiazol-2-yl)phenyl]-1,3- dihydro-2H-1,4-
benzodiazepin-2-one was synthesized. This compound inhibited the in vitro
activity of bovine smooth muscle PDE2 by 91.4% at 10 μ M.


IT 685102-90-3P 685103-00-8P 685103-65-5P
685103-67-7P 685103-68-8P 685103-69-9P
685103-70-2P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(benzodiazepinone inhibitors of cyclic nucleotide phosphodiesterase
PDE2 for use in treatment of nervous system disorders)


RN 685102-90-3 CAPLUS

CN Benzamide, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-6-phenyl-1H-1,4-
benzodiazepin-5-yl)- (CA INDEX NAME)




RN 685103-00-8 CAPLUS

CN Benzamide, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-9-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)



RN 685103-65-5 CAPLUS


CN Benzonitrile, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-9-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)



RN 685103-67-7 CAPLUS


CN 2-Propenoic acid, 3-[3-[5-(3-cyanophenyl)-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-9-yl]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 685103-68-8 CAPLUS

CN Carbamic acid, [3-[3-[5-(3-cyanophenyl)-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-6-yl]phenyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 685103-69-9 CAPLUS

CN Benzonitrile, 3-[9-[3-(3-amino-1-propynyl)phenyl]-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (9CI) (CA INDEX NAME)



RN 685103-70-2 CAPLUS

CN Benzonitrile, 3-[6-[3-(3-amino-1-propynyl)phenyl]-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-5-yl]- (9CI) (CA INDEX NAME)




IT 685103-64-4P 685103-66-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzodiazepinone inhibitors of cyclic nucleotide phosphodiesterase
PDE2 for use in treatment of nervous system disorders)


RN 685103-64-4 CAPLUS

CN Benzonitrile, 3-(2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-6-phenyl-1H-1,4-benzodiazepin-5-yl)- (CA INDEX NAME)




RN 685103-66-6 CAPLUS

CN Carbamic acid, [3-[3-[5-(3-cyanophenyl)-2,3-dihydro-7,8-dimethoxy-1-methyl-2-oxo-1H-1,4-benzodiazepin-9-yl]phenyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1994:323531 CAPLUS Full-text
 DN 120:323531
 TI Synthesis of benzo-fused benzodiazepines employed as probes of the agonist pharmacophore of benzodiazepine receptors
 AU Zhang, Weijiang; Koehler, Konrad F.; Harris, Bradford; Skolnick, Phil; Cook, James M.
 CS Department of Chemistry, University of Wisconsin, Milwaukee, WI, 53201, USA
 SO Journal of Medicinal Chemistry (1994), 37(6), 745-57
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 GI




AB The preparation and in vitro evaluation of benzo-fused benzodiazepines such as I (X = H, F) are described. These "mol. yardsticks" were employed to probe the spatial dimensions of the lipophilic pocket L2 in the benzodiazepine receptor (BzR) cleft and to determine the effect of occupation of L2 with respect to agonist activity. Of the new analogs prepared, the 7,8-benzo-fused benzodiazepine I (X = F) displayed moderately high affinity for the BzR ($IC_{50} = 55$ nM) and exhibited both anticonvulsant ($ED_{50} \approx 15$ mg/kg) and muscle relaxant ($ED_{50} \approx 15$ mg/kg) activity. As expected, II (X = H) interacted with the repulsive regions of interaction, S1 and S2, and exhibited low affinities for BzR. The rigid nature of these mol. yardsticks, especially I was employed to probe the depth of L2. Also, in the case of I full occupation of L2 resulted in an increase in the muscle relaxant effect at the expense of the anticonvulsant/anxiolytic effect.

IT 70740-89-5


RL: RCT (Reactant); RACT (Reactant or reagent)
 (study of pharmacophore of benzodiazepine receptor agonist of
 benzo-fused benzodiazepines)

RN 70740-89-5 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5,7-diphenyl- (9CI) (CA INDEX
 NAME)




L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1990:91212 CAPLUS Full-text
 DN 112:91212
 TI Vertex indexes of molecular graphs in structure-activity relationships: a study of the convulsant-anticonvulsant activity of barbiturates and the carcinogenicity of unsubstituted polycyclic aromatic hydrocarbons
 AU Klopman, G.; Raychaudhury, C.
 CS Dep. Chem., Case West. Reserve Univ., Cleveland, OH, 44106, USA
 SO Journal of Chemical Information and Computer Sciences (1990), 30(1), 12-19
 CODEN: JCISD8; ISSN: 0095-2338
 DT Journal
 LA English
 AB A new methodol. is proposed whereby local distance-based vertex indexes are used in structure-activity studies. It is possible to reconstruct chemical graphs for those indexes found to be relevant to activity. This is essential if the results of structure-activity anal. by methods utilizing graph indexes are to be useful in the design of new active mol. entities. The methodol. is illustrated by applications to the study of the convulsant-anticonvulsant activity of barbiturates and the carcinogenic activity of unsubstituted polycyclic aromatic hydrocarbons.
 IT 70740-89-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (convulsant-anticonvulsant activity of, structure in relation to)
 RN 70740-89-5 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5,7-diphenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1985:197520 CAPLUS Full-text
 DN 102:197520
 TI Use of artificial intelligence in structure-activity correlations of
 anticonvulsant drugs
 AU Klopman, Gilles; Contreras, Renato
 CS Dep. Chem., Case West. Reserve Univ., Cleveland, OH, 44106, USA
 SO Molecular Pharmacology (1985), 27(1), 86-93
 CODEN: MOPMA3; ISSN: 0026-895X
 DT Journal
 LA English
 AB The Computer-Automated Structure Evaluation Program, a new expert system
 capable of automatically developing relevant descriptors for structure-
 activity relationships, has been used to analyze exptl. anticonvulsant
 activity data of a series of 1,3-dihydro-2H-1,4- benzodiazepine-2-one derivs.
 Some significant correlations are observed between the activity of 99
 benzodiazepines against pentylenetetrazole and some relevant mol. fragments
 identified by the program. The utility of the observed relationships and the
 predictive power of the method are discussed.
 IT 70740-89-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (anticonvulsant activity of, structure in relation to)
 RN 70740-89-5 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5,7-diphenyl- (9CI) (CA INDEX
 NAME)




L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1983:612505 CAPLUS Full-text
 DN 99:212505
 TI Studies on the practically carrier-free radiohalogenation of
 receptor-binding 1,4-benzodiazepines with fluorine-18, bromine-75, and
 iodine-123
 AU Scholl, H.
 CS Inst. Chem., Kernforschungsanlage Juelich, Juelich, Fed. Rep. Ger.
 SO Ber. Kernforschungsanlage Juelich (1983), Juel-1851, 161 pp.
 CODEN: BKEJAS; ISSN: 0366-0885
 DT Report
 LA German
 GI




AB Labeled benzodiazepinone I [R = H, R1 = Cl, F, R2 = 77Br; R = Me, R1 = Cl, R2 = 77Br; R = Me, R1 = F, R2 = 75Br, 77Br (II), 123I] were prepared by halogenation of an azo derivative. Thus, I (R = Me, R1 = F, R2 = NO2) was reduced to the amine, diazotized, and condensed with piperidine to give I (R = Me, R1 = F, R2 = piperidinoazo). This was treated with 77Br to give II.
 IT 87951-81-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 87951-81-3 CAPLUS
 CN [7,7'-Bi-2H-1,4-benzodiazepine]-2,2'-dione, 5,5'-bis(2-fluorophenyl)-1,1',3,3'-tetrahydro-1,1'-dimethyl- (9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1980:140418 CAPLUS Full-text
 DN 92:140418
 TI Application of the Free-Wilson model to the analysis of three different
 pharmacological activity tests of benzodiazepines
 AU Borea, P. A.; Gilli, G.; Bertolasi, V.
 CS Ist. Farmacol., Univ. Ferrara, Ferrara, Italy
 SO Farmaco, Edizione Scientifica (1979), 34(12), 1073-82
 CODEN: FRPSAX; ISSN: 0430-0920
 DT Journal
 LA English
 AB The Free-Wilson model has been applied to the anal. of activity data of 55
 benzodiazepines derived from footshock, inclined screen and pentylenetetrazole
 tests. The comparison of the individual group contributions showed a similar
 trend for footshock and inclined screen tests, whereas some differences were
 observed with respect to the pentylenetetrazole test. The most relevant
 differences seemed to be associated with the presence of highly electron-
 withdrawing substituents in positions 7 and 2'.
 IT 70740-89-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (anticonvulsant activity of, structure in relation to)
 RN 70740-89-5 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5,7-diphenyl- (9CI) (CA INDEX
 NAME)



L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1979:432657 CAPLUS Full-text
 DN 91:32657
 TI Quantitative structure-activity relationships and dipole moments of
 anticonvulsants and CNS depressants
 AU Lien, Eric J.; Liao, Richard C. H.; Shinouda, H. G.
 CS Sch. Pharm., Univ. Southern California, Los Angeles, CA, 90033, USA
 SO Journal of Pharmaceutical Sciences (1979), 68(4), 463-5
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English
 AB The anticonvulsant and central nervous system depressant activities of 16 com.
 available antiepileptics were subjected to regression anal. For the maximal
 electroshock seizure test and pentylenetetrazol seizure threshold test, good
 correlations were obtained only after diazepam [439-14-5], clonazepam [1622-
 61-3], and carbamazepine [298-46-4] were deleted; for the median toxic dose
 (rotorod ataxia), all 16 compds. could be included in a single equation using
 log mol. weight, octanol-water partition coefficient and dipole moment (μ)
 terms. For the anticonvulsant activities of 7-substituted 1,4-
 benzodiazepinones, a parabolic equation of π combined with the Hammett σ
 constant gave fair correlations for most derivs. examined in 3 different
 tests. Based upon the correlations obtained, further mol. modifications were
 suggested. The dipole moments of 7 clin. used antiepileptic drugs were
 measured in 1,4-dioxane for the first time.
 IT 70740-89-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); .BIOL (Biological study); USES
 (Uses)
 (anticonvulsant activity of, structure in relation to)
 RN 70740-89-5 CAPLUS
 CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5,7-diphenyl- (9CI) (CA INDEX
 NAME)



L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1974:10247 CAPLUS Full-text

DN 80:10247

TI Quinazolines and 1,4-benzodiazepines. 58. Azido group, a novel pharmacophoric substituent. 7-Azido-5-phenyl-1,4-benzodiazepines

AU Ning, Robert Y.; Sternbach, Leo H.; Pool, William; Randall, Lowell O.

CS Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA

SO Journal of Medicinal Chemistry (1973), 16(8), 879-82

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB 7-Azido-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one (I) [34084-40-7] and some of derivs. had sedative, muscle relaxant, taming, and anticonvulsant effects in mice comparable to those of diazepam and chlordiazepoxide. However, compds. containing a triazole or tetrazole substituent in the 7 position were inactive. The azido compds. were prepared by diazotization of the corresponding 7-amino compds. followed by treatment with HN3.


IT 49702-79-6P 49702-80-9P 49702-81-0P

49702-82-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 49702-79-6 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 7-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-benzotriazol-1-yl)-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 49702-80-9 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-5-phenyl-7-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 49702-81-0 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-7-(2-methyl-2H-tetrazol-5-yl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 49702-82-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-methyl-7-(1-methyl-1H-tetrazol-5-yl)-5-phenyl- (9CI) (CA INDEX NAME)



=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



G1 H,O
 G2 H,Cb,Ak

Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 14:38:15 ON 14 OCT 2007)

FILE 'REGISTRY' ENTERED AT 14:38:29 ON 14 OCT 2007

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 11 S L2
 L4 132 S L2 FUL

FILE 'CAPLUS' ENTERED AT 14:38:59 ON 14 OCT 2007

L5 11 S L4

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
58.44	230.75

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.58	-8.58

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 14:39:48 ON 14 OCT 2007